ENTERIC PATHOGENS - MUCOSAL RESEARCH UNIT

本合同的目的是了解人类粘膜免疫 由肠道细菌感染或接种疫苗产生的反应， 病毒 需要这些信息，以便制定有效的 针对肠道病原体的疫苗接种策略。 承包商将 利用成人志愿者的研究来实现以下目标： 合同 个体将面临基因弱化的挑战 （减毒）或野生型大肠杆菌、沙门氏菌属、志贺氏菌属 种、霍乱弧菌、弯曲杆菌属、幽门螺杆菌、 轮状病毒、其它肠道病毒或其它适当的生物体。 他们的 对这种攻击免疫应答将被广泛表征为 为了确定免疫反应的那些方面， 保护免受野生型生物的攻击。 一旦确定， 将通过迭代方法进一步努力， 免疫反应的保护性方面，通过使用各种 佐剂、递送系统、给药方案或其它方法。 承包商将从 巴尔的摩/华盛顿大都市社区，筛选他们适当的 免疫状态，告诉他们研究的性质及其 目的，在医院的隔离病房进行研究，或 在适当的时候，在门诊病人，并提供必要的后续行动， 所有志愿者的待遇。 还打算让承包者有效互动， 经常与第二个承包商一起进行类似的研究， 呼吸道病原体（贝勒医学院，N 01-AI-65298）。 是 预计这两个小组将取得协同效应 在进一步了解人类粘膜免疫 反应 这样的结果将可能有利于其他疾病的研究。 比那些与消化或呼吸系统相关的更容易。 是 预计这些研究将导致更有效的疫苗 针对大量传染病的战略。

The objective of this contract is to understand the human mucosal immune response generated by infection or vaccination with enteric bacteria and viruses. This information is needed in order to develop effective vaccination strategies against enteric pathogens. The contractor will employ studies of human adult volunteers to accomplish the objectives of the contract. Individuals will be challenged with genetically weakened (attenuated) or wild-type Escherichia coli, Salmonella species, Shigella species, Vibrio cholerae, Campylobacter species, Helicobacter pylori, rotavirus, other enteric viruses, or other appropriate organisms. Their immune response to such challenge will be extensively characterized in order to identify those aspects of the immune response that correlate with protection from challenge by wild-type organisms. Once identified, further efforts will be made through iterative methodology to maximize that protective aspect of the immune response through the use of various adjuvants, delivery systems, dosing schedules or other methods. The contractor will recruit adult volunteers from the Baltimore/Washington metropolitan community, screen them for appropriate immune status, instruct them about the nature of the study and its objectives, perform the studies on an isolation ward in the hospital or in out-patients when appropriate, and provide the necessary follow-up and treatment for all volunteers. It is further intended that the contractor will interact effectively and frequently with a second contractor working on equivalent studies of respiratory pathogens (Baylor College of Medicine, N01-AI-65298). It is anticipated that synergistic effects will be achieved by these two groups in the furthering of our understanding of the human mucosal immune response. Such a result will likely benefit studies of diseases other than those associated with the digestive or respiratory systems. It is anticipated that these studies will lead to more effective vaccine strategies against a large number of infectious diseases.